Microbiome Modulators Slowly Nurture Investor Confidence
Microbiotica Raises £50m Series B
Once deemed an intimidating and risky space, microbiome modulator firms are slowly winning over investors as robust clinical data surface, with one company, Microbiotica, recently hitting an EU financing record.
